Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, highlighting significant growth for its flagship medication, Filspari. The company achieved quarterly net product sales of $126.6 million and a full-year total of $410.5 million, with Filspari alone generating $322 million in 2025, which was a 144% increase year-over-year. This growth was supported by expanded physicia ...